-
IMbrave050 trial results: Atezolizumab combined with bevacizumab can significantly improve RFS in patients with HCC at high risk of recurrence
Recent findings from the phase III IMbrave050 trial presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting have unveiled a significant advancement in the treatment of hepatocellular carcinoma (HCC). The trial investigated the impact of adjuvant therapy with atezolizumab in combination with bevacizumab on recurrence-free survival (RFS) in HCC patients at high…
-
AASLD China Voice | Professor Wei Lai’s Team at Tsinghua Chang Gung: Latest Developments in the Nationwide “MAFLD Epidemiological Survey Research Pro
AASLD China Voice | Professor Wei Lai’s Team at Tsinghua Chang Gung: Latest Developments in the Nationwide “MAFLD Epidemiological Survey Research Project” on Health Check-up Populations Editor’s Note: In 2020,…
-
KEYNOTE-966 Study Published in “The Lancet”: Pembrolizumab Combined with Chemotherapy Brings Significant Survival Benefits to Advanced Biliary Tract
According to the KEYNOTE-966 study results announced at the 2023 American Association for Cancer Research (AACR) annual meeting, adding pembrolizumab on the basis of gemcitabine and cisplatin brings statistically and clinically significant survival benefits to patients with advanced biliary tract cancer. These results validate the outcomes of the randomized phase III TOPAZ-1 study. Encouragingly, this…
-
AEGEAN Trial: New Data on Neoadjuvant Chemotherapy/Immunotherapy + Adjuvant Immunotherapy Released
According to the preliminary results of the phase III AEGEAN trial (NCT03800134) interim analysis presented at the AACR Annual Meeting in 2023, in patients with resectable non-small cell lung cancer (NSCLC), the perioperative durvalumab combined with platinum-based neoadjuvant chemotherapy showed statistically significant improvements in pathological complete response (pCR) and event-free survival (EFS) compared to placebo…
-
Progress of ctDNA in predicting prognosis of patients with urological tumors
Circulating tumor DNA (ctDNA) for predicting tumor prognosis and guiding individualized treatment is a hot topic in malignant tumor research. ctDNA exists in the peripheral blood of tumor patients in a cell-free state and can dynamically evaluate the tumor condition, overcoming tumor heterogeneity biases. The 2023 American Association for Cancer Research (AACR) Annual Meeting was…
-
New KRAS G12C Inhibitor Shows Early Efficacy in Solid Tumors and Previously Treated NSCLC
According to results from the phase 1a/1b LOXO-RAS-20001 study (NCT04956640) showcased at the 2023 American Association for Cancer Research (AACR) annual meeting, the KRAS G12C inhibitor LY3537982 exhibited clinical efficacy in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and other solid tumors.
-
Application of high-throughput next-generation sequencing in diagnosis and treatment of myeloid hematologic malignancies in the era of precision medic
In May 2023, Professor Jun Ma and his team from Harbin Institute of Hematology Oncology published a paper in the Journal of Leukemia & Lymphoma titled “Application of high-throughput next-generation…
-
Exploring New Breast Cancer Risk Genes, Biomarkers, and Prognostic Models at AACR 2023
The American Association for Cancer Research (AACR) held its annual conference from April 14th to 19th, 2023 in Orlando, USA. With numerous reports on clinical, fundamental, and translational cancer research presented each year, this year’s AACR conference delved deep into the realm of breast cancer. Research focused on the analysis of various susceptibility genes and…
Connecting Medical Expertise through Media